AmpliPhi Biosciences (OTC: APHB) is a biopharmaceutical company focused on the discovery, development and commercialization of bacteriophage treatments for bacterial infections. Bacteriophages are viruses that infect, replicate in, and kill bacterial cells while not harming eukaryotic cells. This exclusivity is vital to their use in combating infectious diseases, and their unique mechanism of action compared to traditional antibiotics means they can be used in place of or in conjunction with those therapies. In addition, with the rise of antibiotic resistant bacteria, there is a pressing need for more and better treatments for bacterial infections that are resistant to the effects of antibiotics.
AmpliPhi has three lead compounds currently under development: AmpliPhage-001 is being developed for the treatment of Pseudomonas
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|